{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:20:49Z","timestamp":1786998049888,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.virusres.2020.198146","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:29:08Z","timestamp":1598660948000},"page":"198146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19"],"prefix":"10.1016","volume":"289","author":[{"given":"Shalki","family":"Choudhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om","family":"Silakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2020.198146_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1763199","article-title":"In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by ammoides verticillata components harvested from western Algeria","author":"Abdelli","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virusres.2020.198146_bib0010","doi-asserted-by":"crossref","first-page":"116832","DOI":"10.1016\/j.jns.2020.116832","article-title":"Central nervous system manifestations of COVID-19: a systematic review","volume":"413","author":"Asadi-Pooya","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.virusres.2020.198146_bib0015","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(20)30673-5","article-title":"COVID-19: towards controlling of a pandemic","volume":"395","author":"Bedford","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.virusres.2020.198146_bib0020","series-title":"TMPRSS2 And Furin are Both Essential for Proteolytic Activation and Spread of SARS-CoV-2 in Human Airway Epithelial Cells and Provide Promising Drug Targets","author":"Bestle","year":"2020"},{"key":"10.1016\/j.virusres.2020.198146_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: an update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virusres.2020.198146_bib0030","series-title":"Favipiravir Versus Arbidol for COVID-19: A Randomized Clinical Trial","author":"Chen","year":"2020"},{"key":"10.1016\/j.virusres.2020.198146_bib0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jmgm.2019.06.012","article-title":"hCES1 and hCES2 mediated activation of epalrestat-antioxidant mutual prodrugs: unwinding the hydrolytic mechanism using in silico approaches","volume":"91","author":"Choudhary","year":"2019","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.virusres.2020.198146_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01590-2","article-title":"Drug repurposing against COVID-19: focus on anticancer agents","volume":"39","author":"Ciliberto","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.virusres.2020.198146_bib0045","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.1016\/j.bmc.2014.09.013","article-title":"Structure\u2013activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication","volume":"22","author":"Di Mola","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.virusres.2020.198146_bib0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/ph13030036","article-title":"Bioisosteric replacement as a tool in anti-HIV drug design","volume":"13","author":"Dick","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.virusres.2020.198146_bib0055","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1002\/jcc.21859","article-title":"Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime\/MM\u2013GBSA calculation","volume":"32","author":"Du","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.virusres.2020.198146_bib0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.virusres.2020.198146_bib0065","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1021\/ci100469n","article-title":"Predicting fragment binding poses using a combined MCSS MM-GBSA approach","volume":"51","author":"Haider","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.virusres.2020.198146_bib0070","first-page":"1","article-title":"A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin","author":"Hasan","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.virusres.2020.198146_bib0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.virusres.2020.198146_bib0080","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/jcm9041131","article-title":"Pharmacological therapeutics targeting RNA-dependent RNA polymerase, proteinase and spike protein: from mechanistic studies to clinical trials for COVID-19","volume":"9","author":"Huang","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.virusres.2020.198146_bib0085","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","article-title":"Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol","volume":"114","author":"Kadam","year":"2017","journal-title":"PNAS"},{"key":"10.1016\/j.virusres.2020.198146_bib0090","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1023\/A:1015040217741","article-title":"Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs","volume":"16","author":"Kelder","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.virusres.2020.198146_bib0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.virusres.2020.198146_bib0100","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/minf.201000019","article-title":"Bioisosteric replacement and scaffold hopping in lead generation and optimization","volume":"29","author":"Langdon","year":"2010","journal-title":"Mol. Inform."},{"key":"10.1016\/j.virusres.2020.198146_bib0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2008.10.009","article-title":"Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol","volume":"81","author":"Leneva","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virusres.2020.198146_bib0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead-and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.virusres.2020.198146_bib0115","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.virusres.2020.198146_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104859","article-title":"Candidate drugs against SARS-CoV-2 and COVID-19","volume":"157","author":"McKee","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.virusres.2020.198146_bib0125","series-title":"Drug Repurposing of Approved Drugs Elbasvir, Ledipasvir, Paritaprevir, Velpatasvir, Antrafenine and Ergotamine for Combating COVID19","author":"Mevada","year":"2020"},{"key":"10.1016\/j.virusres.2020.198146_bib0130","article-title":"Computational identification of potential dipeptidyl peptidase (DPP)-IV inhibitors: structure based virtual screening, molecular dynamics simulation and knowledge based SAR studies","volume":"1224","author":"Nath","year":"2020","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.virusres.2020.198146_bib0135","first-page":"1","article-title":"Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC","author":"Pathak","year":"2020","journal-title":"Mol. Divers."},{"key":"10.1016\/j.virusres.2020.198146_bib0140","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1021\/bi700181j","article-title":"Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol","volume":"46","author":"Pecheur","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.virusres.2020.198146_bib0145","unstructured":"QikProp, S., 2015. LLC. New York, NY."},{"key":"10.1016\/j.virusres.2020.198146_bib0150","series-title":"3: Maestro","author":"Release","year":"2019"},{"key":"10.1016\/j.virusres.2020.198146_bib0155","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.26633\/RPSP.2020.40","article-title":"Clinical trials on drug repositioning for COVID-19 treatment","volume":"44","author":"Rosa","year":"2020","journal-title":"Rev. Panam. Salud Publ."},{"key":"10.1016\/j.virusres.2020.198146_bib0160","series-title":"Schr\u00f6dinger Release 2013\u20133: SiteMap, Version 2.9","author":"Schr\u00f6dinger","year":"2013"},{"key":"10.1016\/j.virusres.2020.198146_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117652","article-title":"In silico studies on therapeutic agents for COVID-19: drug repurposing approach","volume":"252","author":"Shah","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.virusres.2020.198146_bib0170","article-title":"MolOpt: a web server for drug design using bioisosteric transformation","author":"Shan","year":"2019","journal-title":"Curr. Comput. Aid Drug Des."},{"key":"10.1016\/j.virusres.2020.198146_bib0175","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1021\/acsmedchemlett.9b00343","article-title":"Scaffold morphing to identify novel DprE1 inhibitors with antimycobacterial activity","volume":"10","author":"Shandil","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.virusres.2020.198146_bib0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bioorg.2018.04.001","article-title":"Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET","volume":"79","author":"Singh","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.virusres.2020.198146_bib0185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijsu.2020.02.034","article-title":"World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)","volume":"76","author":"Sohrabi","year":"2020","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.virusres.2020.198146_bib0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41581-020-0279-4","article-title":"Controversies of renin\u2013angiotensin system inhibition during the COVID-19 pandemic","volume":"16","author":"South","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.virusres.2020.198146_bib0195","doi-asserted-by":"crossref","first-page":"22035","DOI":"10.1039\/C4CP03179B","article-title":"Assessing the performance of MM\/PBSA and MM\/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM\/GBSA and MM\/PBSA rescoring","volume":"16","author":"Sun","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.virusres.2020.198146_bib0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105998","article-title":"Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking the trimerization of viral spike glycoprotein?","volume":"56","author":"Vankadari","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.virusres.2020.198146_bib0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105948","article-title":"A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence","volume":"55","author":"Wang","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.virusres.2020.198146_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12250-020-00212-7","article-title":"A unique protease cleavage site predicted in the spike protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to viral transmissibility","volume":"35","author":"Wang","year":"2020","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virusres.2020.198146_bib0215","series-title":"Statistical Review of Favipiravir Versus Arbidol for COVID-19: A Randomized Clinical Trial","author":"Wilkinson","year":"2020"},{"key":"10.1016\/j.virusres.2020.198146_bib0220","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1016\/j.bmcl.2017.06.074","article-title":"Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin","volume":"27","author":"Wright","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.virusres.2020.198146_bib0225","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.virusres.2020.198146_bib0230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.virusres.2020.198146_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105982","article-title":"Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies","volume":"55","author":"Zhao","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.virusres.2020.198146_bib0240","series-title":"Systemic Analysis of Tissue Cells Potentially Vulnerable to SARS-CoV-2 Infection by the Protein-Proofed Single-Cell RNA Profiling of ACE2, TMPRSS2 and Furin Proteases","author":"Zhou","year":"2020"},{"key":"10.1016\/j.virusres.2020.198146_bib0245","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170220310534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170220310534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T14:11:00Z","timestamp":1759155060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170220310534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":49,"alternative-id":["S0168170220310534"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2020.198146","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2020.198146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"198146"}}